BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37782449)

  • 1. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma.
    Shi S; Wang Q; Du X
    J Appl Genet; 2023 Dec; 64(4):779-796. PubMed ID: 37782449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Forkhead BOX M1 (FOXM1) gene expression in colorectal cancer.
    Rather TB; Parveiz I; Bhat GA; Rashid G; Wani RA; Khan IY; Mudassar S
    Clin Exp Med; 2023 Oct; 23(6):2385-2405. PubMed ID: 36318377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From imaging to clinical outcome: dual-region CT radiomics predicting FOXM1 expression and prognosis in hepatocellular carcinoma.
    Chen X; Tang Y; Wu D; Li R; Lin Z; Zhou X; Wang H; Zhai H; Xu J; Shi X; Zhang G
    Front Oncol; 2023; 13():1278467. PubMed ID: 37817774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.
    Hu K; Xie W; Ni S; Yan S; Tian G; Qi W; Duan Y
    Oncol Rep; 2020 Aug; 44(2):650-660. PubMed ID: 32627005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells.
    Duan N; Hu X; Yang X; Cheng H; Zhang W
    Int J Clin Exp Pathol; 2015; 8(9):10250-60. PubMed ID: 26617733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
    Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
    J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immunological role of FOXM1 in human solid tumors.
    Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
    Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPAG5 promotes osteosarcoma metastasis via activation of FOXM1/MMP2 axis.
    Li Z; Li H; Chen J; Luo H; Zeng J; Yao Y; Duan M
    Int J Biochem Cell Biol; 2020 Sep; 126():105797. PubMed ID: 32668328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.
    Su Z; Wang C; Pan R; Li H; Chen J; Tan J; Tian X; Lin T; Shen J
    Front Immunol; 2022; 13():1028263. PubMed ID: 36275679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.
    Wang W; Guo Z; Yu H; Fan L
    J Cell Biochem; 2019 Apr; 120(4):5435-5443. PubMed ID: 30302807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
    Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
    Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
    Front Immunol; 2022; 13():997765. PubMed ID: 36275664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
    Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
    J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.
    Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V
    Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic role of FOXM1 in human prostate cancer (Review).
    Lee DY; Chun JN; So I; Jeon JH
    Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 38038123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
    Li Y; Zhang T; Zhang Y; Zhao X; Wang W
    Cancer Sci; 2018 Oct; 109(10):3093-3104. PubMed ID: 30099814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.